Source: Google NewsPublished on 2021-02-23
Related Articles:
- The road ahead: 2021 January 25, 2021 # # # # At the start of each year, it is a useful practise to layout what is planned over the next 12 months. The events that are scheduled for the year to come, so that we can keep an eye out for them. Obviously, where 2021 will end actually is unpredictable, but an outline of what is scheduled…
- The road ahead: 2020 January 5, 2020 Here at the SoPD, we are primarily interested in disease modification for Parkinson’s. While there is a great deal of interesting research exploring the causes of the condition, novel symptomatic therapies, and other aspects of Parkinson’s, my focus is generally on the science seeking to slow, stop or reverse the condition. At the start of each year, it is a…
- Monthly Research Review – January 2021 January 31, 2021 # # # # At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during the previous 4 weeks. The post is divided into eight parts based on the type of research: Basic biology Disease mechanism Clinical research New clinical trials Clinical…
- 2019: Year in review December 31, 2019 In this end-of-year post, we review the Parkinson’s research that caught our attention at SoPD HQ in 2019. Month-by-month we will briefly discuss some of the major pieces of research/announcements that have defined the year and advanced our understanding of Parkinson’s. The list is based on nothing more than the author’s personal opinion – apologies to any researchers who…
- Monthly Research Review – August 2019 August 31, 2019 At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during August 2019. The post is divided into seven parts based on the type of research: Basic biology Disease mechanism Clinical research New clinical trials Clinical trial news Other news Review…
- Prevail lands on a Lilly pad December 15, 2020 # # # # 2020 has been a dreadful year for most of the world – burdened by the outbreak and consequences of COVID-19. Despite this, there has been a steady stream of biotech acquisitions related to Parkinson’s which have helped to keep morale high in the PD research community. In October alone, we saw the Portuguese pharmaceutical company Bial…
- Tiny Vesicles Found in Blood Able to Carry Dopamine into Brains of Mice in Parkinson’s Study September 5, 2018 Tiny fatty vesicles that naturally circulate in the blood can effectively carry medications into the central nervous system, including into the brain, an early study in mice suggests. These blood vesicles, called exosomes, were able to successfully deliver dopamine directly to specific areas of the brain affected by Parkinson’s disease. The study, “Dopamine-loaded blood exosomes targeted to brain for better treatment…
- Monthly Research Review – December 2020 December 31, 2020 At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during December 2020. The post is divided into seven parts based on the type of research: Basic biology Disease mechanism Clinical research New clinical trials Clinical trial news Conferences/lectures Other news…
- Coya Therapeutics™ Announces Formation of Scientific Advisory Board - GlobeNewswire February 23, 2021 Coya Therapeutics™ Announces Formation of Scientific Advisory Board GlobeNewswire
- How Tai Chi Helps PD August 5, 2019 Some people call tai chi “meditation in motion,” but we think it should be called “medicine in motion” because of its benefits on Parkinson’s symptoms. If you love watching martial arts movies but never imagined yourself doing the same dashing moves as Bruce Lee, don’t give up on yourself just yet. Tai chi is a Chinese martial art that improves…
- Monthly Research Review – November 2019 November 30, 2019 At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during November 2019. The post is divided into seven parts based on the type of research: Basic biology Disease mechanism Clinical research New clinical trials Clinical trial news Other news Review…
- Coya Therapeutics Completes Merger with Nicoya Health Inc. and Announces $10 Million Series A Financing to Advance Pipeline of Regulatory T cell Therapeutics Optimized for Neurodegeneration and Autoimmune Diseases - BioSpace February 3, 2021 Coya Therapeutics Completes Merger with Nicoya Health Inc. and Announces $10 Million Series A Financing to Advance Pipeline of Regulatory T cell Therapeutics Optimized for Neurodegeneration and Autoimmune Diseases BioSpace
- The Two Faces of Exosomes in Parkinson's Disease: From Pathology to Therapy. February 4, 2021 Related ArticlesThe Two Faces of Exosomes in Parkinson's Disease: From Pathology to Therapy. Neuroscientist. 2021 Feb 03;:1073858421990001 Authors: Izco M, Carlos E, Alvarez-Erviti L Abstract Accumulating evidence suggests that exosomes play a key role in Parkinson's disease (PD). Exosomes may contribute to the PD progression facilitating the spread of pathological alpha-synuclein or activating immune cells. Glial cells also release exosomes,…
- Meet the Newest Davis Phinney Foundation Leaders in Parkinson’s December 8, 2020 We are delighted to announce the creation of The Davis Phinney Foundation Inclusion, Diversity, Equity, and Access (IDEA) Advisory Board. This team of renowned healthcare providers and leaders in the fields of equity and inclusion will play an integral role in our work to better understand and change deeply rooted inequities in healthcare that black, brown, and indigenous communities; LGBTQ+;…
- Molecule Delivered in Small Fatty Vesicles May Be Potential Parkinson’s Therapy, Mouse Study Shows December 15, 2020 Delivering an alpha-synuclein-targeting molecule, called ASO4, in tiny fatty vesicles reduced toxic alpha-synuclein clumps and dopaminergic neuron loss — two main hallmarks of Parkinson’s disease — and lessened motor impairments in a mouse model of the disease. Results of the study add to previous findings suggesting that these vesicles, called exomes, may be a useful tool to deliver therapeutically relevant…
- Top Parkinson’s Experts Join Inhibikase Therapeutics Scientific Advisory Board March 11, 2019 To further support its quest to advance a new therapy for Parkinson’s disease and related disorders, Inhibikase Therapeutics has added three leading researchers to its Scientific Advisory Board (SAB). The pharmaceutical company is developing protein kinase inhibitors for the treatment of neurological infections and neurodegenerative diseases. Its pipeline includes prospective therapies developed from its proprietary Re-engineering Approach with Metabolism Preserved…
- Monthly research review: February 2020 February 29, 2020 At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during February 2020. The post is divided into seven parts based on the type of research: Basic biology Disease mechanism Clinical research New clinical trials Clinical trial news Other news Review…
- Role of Exosomes in Central Nervous System Diseases. October 23, 2019 Related ArticlesRole of Exosomes in Central Nervous System Diseases. Front Mol Neurosci. 2019;12:240 Authors: Liu W, Bai X, Zhang A, Huang J, Xu S, Zhang J Abstract There are many types of intercellular communication, and extracellular vesicles are one of the important forms of this. They are released by a variety of cell types, are heterogeneous, and can roughly be…
- The Evolving Landscape of Exosomes in Neurodegenerative Diseases: Exosomes Characteristics and a Promising Role in Early Diagnosis. January 8, 2021 Related ArticlesThe Evolving Landscape of Exosomes in Neurodegenerative Diseases: Exosomes Characteristics and a Promising Role in Early Diagnosis. Int J Mol Sci. 2021 Jan 04;22(1): Authors: Rastogi S, Sharma V, Bharti PS, Rani K, Modi GP, Nikolajeff F, Kumar S Abstract Neurodegenerative diseases (ND) remains to be one of the biggest burdens on healthcare systems and serves as a leading…
- Regulatory impairment in untreated Parkinson's disease is not restricted to Tregs: other regulatory populations are also involved. November 13, 2019 Related ArticlesRegulatory impairment in untreated Parkinson's disease is not restricted to Tregs: other regulatory populations are also involved. J Neuroinflammation. 2019 Nov 11;16(1):212 Authors: Álvarez-Luquín DD, Arce-Sillas A, Leyva-Hernández J, Sevilla-Reyes E, Boll MC, Montes-Moratilla E, Vivas-Almazán V, Pérez-Correa C, Rodríguez-Ortiz U, Espinoza-Cárdenas R, Fragoso G, Sciutto E, Adalid-Peralta L Abstract BACKGROUND: Parkinson's disease (PD) is the second most common…
- Coya Therapeutics Completes Merger with Nicoya Health Inc. and Announces $10 Million Series A Financing to Advance Pipeline of Regulatory T cell Therapeutics Optimized for Neurodegeneration and Autoimmune Diseases - GlobeNewswire February 3, 2021 Coya Therapeutics Completes Merger with Nicoya Health Inc. and Announces $10 Million Series A Financing to Advance Pipeline of Regulatory T cell Therapeutics Optimized for Neurodegeneration and Autoimmune Diseases GlobeNewswire
- Monthly Research Review – September 2019 September 30, 2019 At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during September 2019. The post is divided into seven parts based on the type of research: Basic biology Disease mechanism Clinical research New clinical trials Clinical trial news Other news Review…